Search

Ryo Kubota

from Seattle, WA
Age ~56

Ryo Kubota Phones & Addresses

  • 5716 56Th St, Seattle, WA 98105
  • 6246 45Th St, Seattle, WA 98115
  • Bothell, WA
  • Kiona, WA
  • Lafayette, CA

Work

Company: Translational research institute for space health Mar 2019 Position: Nasaâ s human research program investigator

Education

School / High School: Harvard Business School Executive Education 2009

Skills

Biotechnology • Drug Discovery • Drug Development • Clinical Development • Lifesciences • Biopharmaceuticals • Life Sciences • Clinical Trials • Pharmaceutical Industry • Oncology • Clinical Research • Immunology • Medical Devices • Pharmacology • Science • Neuroscience • Cell Biology • Commercialization • Technology Transfer • Assay Development • In Vitro • Biochemistry • Ophthalmology • Infectious Diseases • Molecular Biology • Biomarkers • Cancer • R&D • Cro • Regulatory Affairs • Genomics • Toxicology • In Vivo • Cell • Fda • Regulatory Submissions • Glp • Ophthalmologist

Industries

Biotechnology

Resumes

Resumes

Ryo Kubota Photo 1

Chairman, President And Chief Executive Officer

View page
Location:
Seattle, WA
Industry:
Biotechnology
Work:
Translational Research Institute For Space Health
Nasaâ S Human Research Program Investigator

Kubota Pharmaceutical Holdings
Chairman, President and Chief Executive Officer

Acucela Inc. Jan 2015 - Apr 2015
Founder and Chairman

Acucela Inc. Apr 2002 - Dec 2014
Chairman, President, and Chief Executive Officer

Keio University School of Medicine Apr 2002 - Dec 2014
Visiting Professor
Education:
Harvard Business School Executive Education 2009
Keio University 1985 - 1991
Doctor of Medicine, Doctorates, Doctor of Philosophy, Molecular Biology
Skills:
Biotechnology
Drug Discovery
Drug Development
Clinical Development
Lifesciences
Biopharmaceuticals
Life Sciences
Clinical Trials
Pharmaceutical Industry
Oncology
Clinical Research
Immunology
Medical Devices
Pharmacology
Science
Neuroscience
Cell Biology
Commercialization
Technology Transfer
Assay Development
In Vitro
Biochemistry
Ophthalmology
Infectious Diseases
Molecular Biology
Biomarkers
Cancer
R&D
Cro
Regulatory Affairs
Genomics
Toxicology
In Vivo
Cell
Fda
Regulatory Submissions
Glp
Ophthalmologist

Business Records

Name / Title
Company / Classification
Phones & Addresses
1301 2Nd Ave #1900, Seattle, WA 98101
Ryo Kubota
Director, Chief Executive Offi, President, Chief Executive Officer, Chairman And Presdient And Chief Executive Officer
Acucela Inc.
Biotechnology · Commercial Physical Research
1301 2 Ave SUITE 1900, Seattle, WA 98101
21720 23 Dr SE, Bothell, WA 98021
(425) 527-3260, (206) 805-8300, (206) 805-8301, (425) 527-3156
Ryo Kubota
Principal
Acucela
Residential Care Services
1301 2 Ave, Seattle, WA 98101
(206) 805-8300

Publications

Us Patents

Methods And Systems For Extended In Vitro Culture Of Neuronal Cells

View page
US Patent:
7312025, Dec 25, 2007
Filed:
Jul 11, 2003
Appl. No.:
10/618076
Inventors:
Ryo Kubota - Seattle WA, US
Thomas A Reh - Seattle WA, US
Andrew J Fischer - Hilliard OH, US
Assignee:
University of Washington - Seattle WA
International Classification:
C12N 5/06
C12Q 1/00
C12Q 1/02
US Classification:
435 4, 435347, 435368, 435373
Abstract:
A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.

Amine Derivative Compounds For Treating Ophthalmic Diseases And Disorders

View page
US Patent:
8076516, Dec 13, 2011
Filed:
Oct 22, 2008
Appl. No.:
12/256415
Inventors:
Ian L. Scott - Monroe WA, US
Vladimir A. Kuksa - Kenmore WA, US
Mark W. Orme - Seattle WA, US
Feng Hong - Bellevue WA, US
Ryo Kubota - Seattle WA, US
Assignee:
Acucela, Inc. - Bothell WA
International Classification:
A61K 31/135
C07C 211/00
US Classification:
564305, 514649
Abstract:
Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

Styrenyl Derivative Compounds For Treating Ophthalmic Diseases And Disorders

View page
US Patent:
8420863, Apr 16, 2013
Filed:
Jan 27, 2012
Appl. No.:
13/360285
Inventors:
Ian Leslie Scott - Monroe WA, US
Vladimir Aleksandrovich Kuksa - Seattle WA, US
Anna Gall - Woodinville WA, US
Mark W. Orme - Seattle WA, US
Jennifer Gage - Kenmore WA, US
Qin Jiang - Latham NY, US
Lana Michele Rossiter - Clifton Park NY, US
Ryo Kubota - Seattle WA, US
Assignee:
Acucela, Inc. - Bothell WA
International Classification:
C07C 211/03
A61K 31/135
US Classification:
564383, 514654
Abstract:
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Amine Derivative Compounds For Treating Ophthalmic Diseases And Disorders

View page
US Patent:
8450527, May 28, 2013
Filed:
Oct 21, 2011
Appl. No.:
13/278909
Inventors:
Ian L. Scott - Monroe WA, US
Vladimir A. Kuksa - Kenmore WA, US
Mark W. Orme - Seattle WA, US
Feng Hong - Bellevue WA, US
Thomas L. Little - Redmond WA, US
Ryo Kubota - Seattle WA, US
Assignee:
Acucela Inc. - Seattle WA
International Classification:
C07C 211/00
A01N 33/02
US Classification:
564305, 514646
Abstract:
Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

Extended Primary Retinal Cell Culture And Stress Models, And Methods Of Use

View page
US Patent:
20050059148, Mar 17, 2005
Filed:
Jul 30, 2004
Appl. No.:
10/903880
Inventors:
Ryo Kubota - Seattle WA, US
Assignee:
Acucela, Inc. - Seattle WA
International Classification:
C12N005/08
A61K031/203
A61K031/16
A61N001/00
US Classification:
435368000, 514559000, 514613000, 607088000
Abstract:
A cell culture system related to extended in vitro culture of mature retinal cells and methods for preparing the cell culture system are provided. Also provided is a retinal cell culture stress model related to extended in vitro culture of mature retinal cells in the presence of a stressor and methods for using the cell culture stress model. The invention provides a cell culture system comprising a long-term culture of mature retinal cells, without requiring addition of other types of non-retinal cells such as purified glia, or cells isolated from ciliary bodies within the eye, and the addition of a stressor such as light, A2E, cigarette smoke condensate, glutamate, or hydrostatic pressure. Methods for identifying bioactive agents that alter viability, neurodegeneration, or survival of retinal cells using the retinal cell culture stress system are also provided.

Compositions And Methods For Diagnosing And Treating Retinal Diseases

View page
US Patent:
20060252107, Nov 9, 2006
Filed:
Feb 22, 2006
Appl. No.:
11/361027
Inventors:
Ryo Kubota - Seattle WA, US
Krzysztof Palczewski - , US
Anna Gall - Woodinville WA, US
Assignee:
Acucela, Inc. - Seattle WA
International Classification:
G01N 33/53
C07K 16/18
C07K 14/47
C07D 213/55
C07D 213/20
C12N 5/06
US Classification:
435007920, 530387100, 530409000, 435326000, 546341000, 546347000
Abstract:
The present invention relates generally to the preparation and use of retinoid N-retinylidene-N-retinyl-ethanolamine (A2E) conjugated to a carrier polypeptide and to the preparation and use of antibodies that bind specifically to A2E. The invention relates to the use of A2E conjugates as immunogens or vaccines and to the use of A2E specific antibodies for treatment of ophthalmic diseases. Provided herein are methods for enhancing retinal neuronal cell survival, including photoreceptor cell survival, using antibodies that specifically bind to A2E or by inducing an immune response using an A2E immunoconjugate. Enhancing survival of photoreceptor cells or decreasing accumulation of A2E in the eye using the A2E immunoconjugates or A2E specific antibodies is useful for treatment of ophthalmic diseases such as macular degeneration.

Extended Primary Retinal Cell Culture And Stress Models, And Methods Of Use

View page
US Patent:
20080003634, Jan 3, 2008
Filed:
Jun 5, 2007
Appl. No.:
11/758480
Inventors:
Ryo Kubota - Seattle WA, US
Assignee:
ACUCELA, INC. - Bothell WA
International Classification:
C12N 5/06
C12Q 1/02
US Classification:
435029000, 435347000
Abstract:
A cell culture system related to extended in vitro culture of mature retinal cells and methods for preparing the cell culture system are provided. Also provided is a retinal cell culture stress model related to extended in vitro culture of mature retinal cells in the presence of a stressor and methods for using the cell culture stress model. The invention provides a cell culture system comprising a long-term culture of mature retinal cells, without requiring addition of other types of non-retinal cells such as purified glia, or cells isolated from ciliary bodies within the eye, and the addition of a stressor such as light, A2E, cigarette smoke condensate, glutamate, or hydrostatic pressure. Methods for identifying bioactive agents that alter viability, neurodegeneration, or survival of retinal cells using the retinal cell culture stress system are also provided.

Methods And Systems For Extended In Vitro Culture Of Neuronal Cells

View page
US Patent:
20080175826, Jul 24, 2008
Filed:
Nov 16, 2007
Appl. No.:
11/985856
Inventors:
Ryo Kubota - Seattle WA, US
Thomas A. Reh - Seattle WA, US
Andrew J. Fischer - Hilliard OH, US
Assignee:
University of Washington - Seattle WA
International Classification:
A61K 35/12
C12N 5/06
A61P 27/02
C12Q 1/02
US Classification:
424 937, 435325, 435373, 435 29
Abstract:
A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
Ryo Kubota from Seattle, WA, age ~56 Get Report